Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Teva
US Department of Justice
Dow
Julphar
Boehringer Ingelheim
Farmers Insurance
Chubb
Fish and Richardson
Johnson and Johnson

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,731,989

« Back to Dashboard

Summary for Patent: 7,731,989
Title:Gastric retained gabapentin dosage form
Abstract:A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Inventor(s): Berner; Bret (El Granada, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M. (Cupertino, CA)
Assignee: Depomed, Inc. (Menlo Park, CA)
Application Number:12/239,591
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation;

Drugs Protected by US Patent 7,731,989

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed Inc GRALISE gabapentin TABLET;ORAL 022544-001 Jan 28, 2011 BX RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Depomed Inc GRALISE gabapentin TABLET;ORAL 022544-002 Jan 28, 2011 BX RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,731,989

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,592,481 Gastric retentive gabapentin dosage forms and methods for using same ➤ Try a Free Trial
7,438,927 Methods of treatment using a gastric retained gabapentin dosage ➤ Try a Free Trial
8,192,756 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,409,613 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,580,303 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,231,905 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,333,991 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,440,232 Methods of treatment using a gastric retained gabapentin dosage ➤ Try a Free Trial
8,333,992 Gastric retained gabapentin dosage form ➤ Try a Free Trial
8,252,332 Gastric retained gabapentin dosage form ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,731,989

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006332690 ➤ Try a Free Trial
Canada 2464322 ➤ Try a Free Trial
Canada 2575555 ➤ Try a Free Trial
Canada 2635466 ➤ Try a Free Trial
China 101484153 ➤ Try a Free Trial
Denmark 1439825 ➤ Try a Free Trial
European Patent Office 1439825 ➤ Try a Free Trial
European Patent Office 1773311 ➤ Try a Free Trial
European Patent Office 1976503 ➤ Try a Free Trial
European Patent Office 2266539 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
Johnson and Johnson
UBS
US Army
Cantor Fitzgerald
Teva
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot